Intraosseous (IO) access devices can provide vascular access by penetrating surface tissues and underlying hard bone cortex layers to place an access needle and provide access to a medullary cavity of a bone. Fluids and medications can flow through the needle lumen and into the medullary cavity to infuse into the vascular system. IO access events are typically performed in emergent situations where vascular access is rapidly required and/or direct venous access is not possible.
Patients who require IO access report experiencing increased pain during infusion rather than during penetration of the skin surface tissues or bone cortex. The cause of pain may be due to increased pressure in the medullary cavity due to the infused fluids and/or medication. Angling the needle during insertion may direct medication towards larger volumes of the medullary cavity, e.g. the tibial tuberosity, reducing the pressure within the medullary cavity, and in turn reducing discomfort. Further, angling the needle during penetration can mitigate “backwalling,” where the access needle traverses the medullary cavity and penetrates the far wall of bone cortex. Disclosed herein are angled intraosseous access systems including an angled guide plate and an angled guide block, and associated methods thereof that address the foregoing.
Disclosed herein is an angled intraosseous access system including, a needle assembly including a needle defining a needle axis and configured to access a medullary cavity of a bone, a driver rotatably coupled to the needle assembly and configured to advance the needle through a bone cortex to access the medullary cavity, and one or both of a guide plate and a guide block configured to engage a skin surface and align the needle axis at a predetermined angle relative to a longitudinal axis of the medullary cavity.
In some embodiments, the predetermined angle is between 1°-90° relative to the longitudinal axis of the medullary cavity. In some embodiments, one of the guide plate or the guide block includes a concave or convex skin engaging surface configured to engage the skin surface. In some embodiments, the guide plate is coupled to the guide block. In some embodiments, one of the guide plate or the guide block includes a guide recess configured to engage a fiduciary body part and align the needle with a target location. In some embodiments, the guide recess is disposed on a first portion that is slidably engaged with a second portion of one of the guide plate or the guide block which is coupled to the needle.
In some embodiments, the guide block includes a first series of notches and a second series of notches each configured to receive a portion of the driver, the first series of notches configured to align the needle axis with a first predetermined angle, the second series of notches configured to align the needle axis with a second predetermined angle different from the first predetermined angle. In some embodiments, the guide plate defines a channel configured to receive the needle therethrough and maintain the needle at the predetermined angle. In some embodiments, one of the guide plate or the guide block is releasably engaged with the driver body.
In some embodiments, one or both of the guide plate and the guide block includes an adhesive disposed on a surface thereof and configured to adhere to one or both of the driver and the skin surface. In some embodiments, a portion of the guide plate is configured to abut against a portion of the needle assembly to prevent a distal tip of the needle from backwalling a far wall of the medullary cavity.
Also disclosed is a method of accessing a medullary cavity including, engaging a skin engaging surface of a guide plate with a skin surface, aligning a needle of an intraosseous access system with a channel of the guide plate, the channel extending at a predetermined angle relative to the skin engaging surface, and advancing the needle through the channel to access the medullary cavity at the predetermined angle.
In some embodiments, the predetermined angle is between 1°-90° relative to a longitudinal axis of the medullary cavity. In some embodiments, the skin engaging surface includes a concave or a convex portion configured to engage the skin surface. In some embodiments, the method further includes coupling the guide plate with a guide block configured to engage the skin surface and a driver of the intraosseous access system and maintain an axis of the driver at the predetermined angle. In some embodiments, the method further includes engaging a guide recess, disposed on the skin engaging surface, with a fiduciary body part to align the needle with a target location.
In some embodiments, the method further includes sliding a first portion of the guide plate including the guide recess disposed thereon, relative to a second portion of the guide plate including the channel, to align the needle with a target location. In some embodiments, the method further includes adhering a portion of the guide plate to one of the driver or the skin surface. In some embodiments, the method further includes abutting a portion of a needle hub, coupled to the needle against a surface of the guide plate to prevent a distal tip of the needle from backwalling a far wall of the medullary cavity.
Also disclosed is a method of accessing a medullary cavity including, engaging a portion of a driver of an intraosseous access system with a surface of the guide block, engaging a skin engaging surface of the guide block with a skin surface, aligning an axis of a needle of the intraosseous access system with a predetermined angle, and advancing the needle along the needle axis to access the medullary cavity at the predetermined angle.
In some embodiments, the predetermined angle is between 1°-90° relative to a longitudinal axis of the medullary cavity. In some embodiments, the method further includes engaging a guide recess disposed on the skin engaging surface with a fiduciary body part to align the needle with a target location. In some embodiments, the method further includes sliding a first portion of the guide block including the guide recess disposed thereon, relative to a second portion of the guide block to align the needle with a target location. In some embodiments, the method further includes engaging the portion of the driver with one of a first series of notches or a second series of notches to align the axis of the needle axis with one of a first predetermined angle or a second predetermined angle, different from the first predetermined angle.
These and other features of the concepts provided herein will become more apparent to those of skill in the art in view of the accompanying drawings and following description, which describe particular embodiments of such concepts in greater detail.
A more particular description of the present disclosure will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
Before some particular embodiments are disclosed in greater detail, it should be understood that the particular embodiments disclosed herein do not limit the scope of the concepts provided herein. It should also be understood that a particular embodiment disclosed herein can have features that can be readily separated from the particular embodiment and optionally combined with or substituted for features of any of a number of other embodiments disclosed herein.
Regarding terms used herein, it should also be understood the terms are for the purpose of describing some particular embodiments, and the terms do not limit the scope of the concepts provided herein. Ordinal numbers (e.g., first, second, third, etc.) are generally used to distinguish or identify different features or steps in a group of features or steps, and do not supply a serial or numerical limitation. For example, “first,” “second,” and “third” features or steps need not necessarily appear in that order, and the particular embodiments including such features or steps need not necessarily be limited to the three features or steps. Labels such as “left,” “right,” “top,” “bottom,” “front,” “back,” and the like are used for convenience and are not intended to imply, for example, any particular fixed location, orientation, or direction. Instead, such labels are used to reflect, for example, relative location, orientation, or directions. Singular forms of “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
With respect to “proximal,” a “proximal portion” or a “proximal-end portion” of, for example, a needle disclosed herein includes a portion of the needle intended to be near a clinician when the needle is used on a patient. Likewise, a “proximal length” of, for example, the needle includes a length of the needle intended to be near the clinician when the needle is used on the patient. A “proximal end” of, for example, the needle includes an end of the needle intended to be near the clinician when the needle is used on the patient. The proximal portion, the proximal-end portion, or the proximal length of the needle can include the proximal end of the needle; however, the proximal portion, the proximal-end portion, or the proximal length of the needle need not include the proximal end of the needle. That is, unless context suggests otherwise, the proximal portion, the proximal-end portion, or the proximal length of the needle is not a terminal portion or terminal length of the needle.
With respect to “distal,” a “distal portion” or a “distal-end portion” of, for example, a needle disclosed herein includes a portion of the needle intended to be near or in a patient when the needle is used on the patient. Likewise, a “distal length” of, for example, the needle includes a length of the needle intended to be near or in the patient when the needle is used on the patient. A “distal end” of, for example, the needle includes an end of the needle intended to be near or in the patient when the needle is used on the patient. The distal portion, the distal-end portion, or the distal length of the needle can include the distal end of the needle; however, the distal portion, the distal-end portion, or the distal length of the needle need not include the distal end of the needle. That is, unless context suggests otherwise, the distal portion, the distal-end portion, or the distal length of the needle is not a terminal portion or terminal length of the needle.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.
In an embodiment, the driver 112 can include a drive spring, electric motor, or similar electrical, mechanical, electro-mechanical, or kinetic mechanism configured to rotate the needle assembly 120 and drill the needle assembly into a bone of a patient. In an embodiment, the needle assembly 120 can include a needle 124 defining a lumen and supported by a needle hub 126. The needle assembly 120 can further include an obturator 122 disposed within the lumen of the needle 124 and supported by an obturator hub 128. The obturator 122 can be configured to prevent tissue and bone fragments from entering the needle lumen during a placement event and occluding a fluid flow through the needle lumen. Once the needle 124 has been placed, the driver 110 and obturator 122 can be removed. Fluids and/or medications can flow through the needle lumen and into the medullary cavity 70 to infuse into the vasculature of the patient. Further details and embodiments of IO access systems can be found, for example in the following published applications: US 2021/0093354, US 2021/0093355, US 2021/0093358, US 2021/0093356, US 2021/0093357, US 2021/0137558, WO 2018/075694, WO 2018/165334, and WO 2018/165339, each of which are incorporated by reference in its entirety herein.
In an embodiment, the guide plate 130 includes a body 131 defining a skin engaging surface 138, and a channel 132 extending at an angle (θ) relative to a longitudinal axis of the body 131. In an embodiment, the skin engaging surface 138 can be a bottom surface of the body 131. However, it will be appreciated that the skin engaging surface 138 can include one or more surfaces of the body 131. In an embodiment, the skin engaging surface 138 of the guide plate 130 can engage a skin surface 76 and align the channel 132 at an angle (θ) relative thereto. In an embodiment, the guide plate 130 align the channel 132 at an angle (θ) relative to a longitudinal axis 60 of the medullary cavity 70. In an embodiment, the angle (θ) of the channel 132 can be between 1° and 90°. In an embodiment, the angle (θ) of the channel 132 can be between 10°-75°. In an embodiment, the angle (θ) of the channel 132 can be substantially 45°, however greater or lesser angles are also contemplated.
In an embodiment, a diameter of the channel 132 can be equal to or slightly larger than a diameter of the needle 124. As such, the needle 124 can slidably engage the channel 132 and substantially align an axis 62 of the needle 124 with an axis of the channel 132. In some embodiments, the diameter of the guide plate channel 132 may be a consistent diameter along the length thereof In some embodiments, the guide plate channel 132 or portion thereof may define a tapered shape, having a greater diameter proximate a first end relative to a second end, opposite the first end. In some embodiments, an entrance of the guide plate channel 132 may be tapered to facilitate aligning a needle 124 with the channel 132.
In an exemplary method of use, a user can engage a skin engaging surface 138 of the guide plate 130 with a skin surface 76 and align the channel 132 with a target insertion site. The user can then align the needle 124 with the channel 132 and advance a distal tip 129 of the needle 124 through the channel 132. Advancing the needle 124 through the channel 132 can align an axis 62 of the needle 124 with the axis of the channel 132. A user can then actuate the driver 112 to rotate the needle assembly 120 and “drill” the needle 124 into the patient. The needle 124 can then penetrate the surface tissues 74, hard bone cortex 72 and the medullary cavity 70 at the predetermined angle (θ) defined by the channel 132.
In an embodiment, the guide plate 130 can be coupled to the IO access system 110 and the guide plate 130 can be slidably engaged with the needle 124. As such, a user can support the skin engaging surface 138 against the skin surface 76 and the guide plate 130 can further support the IO access system 110 with the needle axis 62 aligned with the channel 132. The user can then actuate the driver 112 and urge the IO access system 110 including the needle 124 along the needle axis 62 at the predetermined angle (θ) defined by the channel 132. The needle 124 can slide through the channel 132 to penetrate the bone at the predetermined angle (θ), as described herein.
In an embodiment, the guide plate 130 can be coupled to the IO access system 110, and the needle assembly 120 can be slidably engaged relative to the IO access system 110 and guide plate 130 assembly. As such, a user can support the skin engaging surface 138 against the skin surface 76 and the guide plate 130 can further support the IO access system 110 with the needle axis 62 aligned with the channel 132. The user can then actuate the driver 112 and the IO access system 110 can urge the needle 124 along the needle axis 62 to penetrate the bone at the predetermined angle (θ), as described herein.
Advantageously, the insertion angle (θ) of the needle 124 can direct a fluid flow through the needle lumen towards the wider regions of the medullary cavity 70, for example at a head of the bone, and can reduce the pressure within the medullary cavity 70 as the fluids and/or medications are transfused. Advantageously, the guide plate 130 can be configured to align the needle 124 at an angle (θ) relative to the axis 60 of the medullary cavity 70 and can increase the penetrable depth (d) of the medullary cavity 70. As shown in
In an embodiment, as shown in
In an embodiment, as shown in
In an embodiment, as shown in
In an embodiment, the guide block 230 can be integrally formed with the driver body 114. In an embodiment, the guide block 230 can be coupled to a portion of the driver body 114 using adhesive, bonding, welding, bolts, screws, or similar fasteners, or similar suitable means. In an embodiment, the guide block 230 can be releasably coupled with the driver body 114 using a clip, latch, interference fit, press-fit, or snap-fit engagement, or similar suitable mechanism.
In an embodiment, a user can grasp the driver body 114 with the guide block 230 coupled thereto, and engage the skin engaging surface 238 with the skin surface 76 of the patient. As such, an axis 62 of the needle 124 can be positioned at a predetermined angle (θ) relative to the axis 60 of the medullary cavity 70, as described herein.
In an embodiment, the IO access system 110 can be slidably engaged with the guide block 230 along the axis 62 of the needle 124. In an embodiment, the needle assembly 120 or portions thereof can be slidable relative to one or both of the driver 112 and the guide block 230, along the axis 62 of the needle 124. As such, the skin engaging surface 238 of the guide block 230 can engage the skin surface 76 and angle the axis 62 of the needle 124 relative to the axis 60 of the medullary cavity 70, as described herein. The needle 124 can then slide along the needle axis 62 through the surface tissues 74, bone cortex 72, and access the medullary cavity 70, as described herein.
In an embodiment, as shown in
In an embodiment, as shown in
In an embodiment, the guide plate 130 can be integrally formed with the guide block 230. In an embodiment, the guide plate 130 can be coupled to a portion of the guide block 230 using adhesive, bonding, welding, bolts, screws, or similar fasteners, or similar suitable means. In an embodiment, the guide plate 130 can be releasably coupled with the guide block 230 using a clip, latch, interference fit engagement, press-fit engagement, snap-fit engagement, hook, tab, slot, or similar suitable mechanism, or combinations thereof. Advantageously, the guide plate 130 and the guide block 230 being coupled together can offer increased stability during a medullary access event to ensure accurate placement of the access needle 124.
In an embodiment, one or more surfaces of the guide plate body 131 or the guide block body 231 can include an adhesive or the like. For example, the adhesive surface can be disposed on a skin engaging surface 138, 238 to facilitate securing the guide plate 130 or guide block 230 to the skin surface 76. In an embodiment, the adhesive surface can be configured to secure one or both of the guide plate 130 and the guide block 230 relative to the IO access system 110. In an embodiment, one or more surfaces of the guide plate 131 or the guide block body 231 can include a material, e.g. silicone rubber, or the like, having a high frictional coefficient to facilitate securing the guide plate 130 or guide block 230 relative to the skin surface 76, or to the IO access system 110, or combinations thereof.
As shown in
Advantageously, the guide block 230 including the guide recess 290 can quickly and intuitively align the needle 124 with a target area of the bone, e.g. the widest portion of the medullary cavity 70, during an emergency placement event where time and availability of trained personnel may be limited. Further, the guide block 230 can angle the needle 124 relative to the axis 60 of the medullary cavity 70 to further increase a penetrable depth for the needle 124.
In an embodiment, a portion of the guide plate 130 or the guide block 230 can be slidably engaged therewith, to allow a user to adjust the position of the guide recess 290 relative to the needle 124. For example, as shown in
In an exemplary method of use, the guide plate 130 and guide block 230 assembly can engage a skin surface 76 of a patient. In an embodiment, a concave or convex skin engaging surface 138, 238 can engage a curved skin surface 76 of the patient. In an embodiment, a guide recess 290 can engage a fiduciary body part 78 to align the needle 124 with a target area. In an embodiment, the user can adjust a first portion 230A of the guide block 230 relative to a second portion 230B and engage the guide recess 290 with the fiduciary body part 78. In an embodiment, the user can align the needle 124 with the channel 132. In an embodiment, the needle 124 can be “preloaded” within the channel 132 prior to the system 300 engaging the skin surface 76. The user can then actuate the driver 112 to rotate the needle assembly 120. In an embodiment, the IO access system 100 can slide relative to one of the guide plate 130 or the guide block 230 to advance the needle 124 through the channel 132. In an embodiment, the needle assembly 120 can advance through the channel 132 relative to the driver 112. The needle can then penetrate the bone at the predetermined angle (θ) to access the medullary cavity 70, as described herein.
For example, as shown in
In an exemplary method of use, a skin engaging surface 438 of the guide block 430 can engage a skin surface 76 of the patient. The user can align a portion of the driver body 114 with one of the first series of notches 432A or the second series of notches 432B to selectively align an axis 62 of the needle 124 with one of the first angle (θ1) or the second angle (θ2). The user can then actuate the driver 112 to rotate the needle assembly 120 and advance the needle 124 into the medullary cavity 70, as described herein, at one of the first angle (θ1) or the second angle (θ2).
While some particular embodiments have been disclosed herein, and while the particular embodiments have been disclosed in some detail, it is not the intention for the particular embodiments to limit the scope of the concepts provided herein. Additional adaptations and/or modifications can appear to those of ordinary skill in the art, and, in broader aspects, these adaptations and/or modifications are encompassed as well. Accordingly, departures may be made from the particular embodiments disclosed herein without departing from the scope of the concepts provided herein.
This application claims the benefit of priority to U.S. Provisional Application No. 63/069,988, filed Aug. 25, 2020, which is incorporated by reference in its entirety into this application.
Number | Name | Date | Kind |
---|---|---|---|
2773501 | Young | Dec 1956 | A |
3071135 | Baldwin et al. | Jan 1963 | A |
3261594 | Michel | Jul 1966 | A |
3734207 | Fishbein | May 1973 | A |
3753432 | Guerra | Aug 1973 | A |
3804544 | Adams | Apr 1974 | A |
3811442 | Maroth | May 1974 | A |
3815605 | Schmidt et al. | Jun 1974 | A |
3991765 | Cohen | Nov 1976 | A |
4266555 | Jamshidi | May 1981 | A |
4314565 | Lee | Feb 1982 | A |
4342724 | Narra | Aug 1982 | A |
4381777 | Garnier | May 1983 | A |
4383530 | Bruno | May 1983 | A |
4562844 | Carpenter et al. | Jan 1986 | A |
4736742 | Alexson et al. | Apr 1988 | A |
4787893 | Villette | Nov 1988 | A |
4889529 | Haindl | Dec 1989 | A |
4952207 | Lemieux | Aug 1990 | A |
4964854 | Luther | Oct 1990 | A |
4969870 | Kramer et al. | Nov 1990 | A |
5040542 | Gray | Aug 1991 | A |
5042558 | Hussey et al. | Aug 1991 | A |
5053017 | Chamuel | Oct 1991 | A |
5122114 | Miller et al. | Jun 1992 | A |
5207697 | Carusillo et al. | May 1993 | A |
5263939 | Wortrich | Nov 1993 | A |
5290267 | Zimmermann | Mar 1994 | A |
5312364 | Jacobs | May 1994 | A |
5332398 | Miller et al. | Jul 1994 | A |
5364367 | Banks et al. | Nov 1994 | A |
5372583 | Roberts et al. | Dec 1994 | A |
5384103 | Miller | Jan 1995 | A |
5406940 | Melzer et al. | Apr 1995 | A |
5451210 | Kramer et al. | Sep 1995 | A |
5554154 | Rosenberg | Sep 1996 | A |
5575780 | Saito | Nov 1996 | A |
5591188 | Waisman | Jan 1997 | A |
5601559 | Melker et al. | Feb 1997 | A |
5667509 | Westin | Sep 1997 | A |
5688249 | Chang et al. | Nov 1997 | A |
5694019 | Uchida et al. | Dec 1997 | A |
5779708 | Wu | Jul 1998 | A |
5817052 | Johnson et al. | Oct 1998 | A |
5853393 | Bogert | Dec 1998 | A |
5868711 | Kramer | Feb 1999 | A |
5885293 | McDevitt | Mar 1999 | A |
5927976 | Wu | Jul 1999 | A |
5960797 | Kramer et al. | Oct 1999 | A |
5967143 | Klappenberger | Oct 1999 | A |
6018227 | Kumar et al. | Jan 2000 | A |
6056165 | Speranza | May 2000 | A |
6104162 | Sainsbury et al. | Aug 2000 | A |
6117108 | Woehr et al. | Sep 2000 | A |
6135769 | Kwan | Oct 2000 | A |
6159161 | Hodosh | Dec 2000 | A |
6199664 | Tkaczyk et al. | Mar 2001 | B1 |
6210373 | Allmon | Apr 2001 | B1 |
6228088 | Miller et al. | May 2001 | B1 |
6247928 | Meller et al. | Jun 2001 | B1 |
6270484 | Yoon | Aug 2001 | B1 |
6273715 | Meller et al. | Aug 2001 | B1 |
6419490 | Kitchings Weathers, Jr. | Jul 2002 | B1 |
6458117 | Pollins, Sr. | Oct 2002 | B1 |
6527778 | Athanasiou et al. | Mar 2003 | B2 |
6547561 | Meller et al. | Apr 2003 | B2 |
6602214 | Heinz et al. | Aug 2003 | B2 |
6626887 | Wu | Sep 2003 | B1 |
6629959 | Kuracina et al. | Oct 2003 | B2 |
6641395 | Kumar et al. | Nov 2003 | B2 |
6652490 | Howell | Nov 2003 | B2 |
6692471 | Boudreaux | Feb 2004 | B2 |
6761726 | Findlay et al. | Jul 2004 | B1 |
6814734 | Chappuis et al. | Nov 2004 | B2 |
6830562 | Mogensen et al. | Dec 2004 | B2 |
6875219 | Arramon et al. | Apr 2005 | B2 |
6905486 | Gibbs | Jun 2005 | B2 |
6916292 | Morawski et al. | Jul 2005 | B2 |
6984213 | Horner et al. | Jan 2006 | B2 |
6997907 | Safabash et al. | Feb 2006 | B2 |
7112191 | Daga | Sep 2006 | B2 |
7135031 | Flint | Nov 2006 | B2 |
7214208 | Vaillancourt et al. | May 2007 | B2 |
7347838 | Kulli | Mar 2008 | B2 |
7347840 | Findlay et al. | Mar 2008 | B2 |
7407493 | Cane' | Aug 2008 | B2 |
7458954 | Ferguson et al. | Dec 2008 | B2 |
7513888 | Sircom et al. | Apr 2009 | B2 |
7530965 | Villa et al. | May 2009 | B2 |
7534227 | Kulli | May 2009 | B2 |
7569033 | Greene et al. | Aug 2009 | B2 |
7582102 | Heinz et al. | Sep 2009 | B2 |
7588559 | Aravena et al. | Sep 2009 | B2 |
7658725 | Bialecki et al. | Feb 2010 | B2 |
7670328 | Miller | Mar 2010 | B2 |
7699807 | Faust et al. | Apr 2010 | B2 |
7699850 | Miller | Apr 2010 | B2 |
7736332 | Carlyon et al. | Jun 2010 | B2 |
7749225 | Chappuis et al. | Jul 2010 | B2 |
7798994 | Brimhall | Sep 2010 | B2 |
7811260 | Miller et al. | Oct 2010 | B2 |
7815642 | Miller | Oct 2010 | B2 |
7828774 | Harding et al. | Nov 2010 | B2 |
7833204 | Picha | Nov 2010 | B2 |
7842038 | Haddock et al. | Nov 2010 | B2 |
7850620 | Miller et al. | Dec 2010 | B2 |
7850650 | Breitweiser | Dec 2010 | B2 |
D633199 | MacKay et al. | Feb 2011 | S |
7899528 | Miller et al. | Mar 2011 | B2 |
7905857 | Swisher | Mar 2011 | B2 |
7951089 | Miller | May 2011 | B2 |
7955297 | Radmer et al. | Jun 2011 | B2 |
7972339 | Nassiri et al. | Jul 2011 | B2 |
7976502 | Baid | Jul 2011 | B2 |
8038038 | Hillhouse et al. | Oct 2011 | B2 |
8038664 | Miller et al. | Oct 2011 | B2 |
8043253 | Kraft et al. | Oct 2011 | B2 |
8043265 | Abe et al. | Oct 2011 | B2 |
8142365 | Miller | Mar 2012 | B2 |
8152771 | Mogensen et al. | Apr 2012 | B2 |
8162904 | Takano et al. | Apr 2012 | B2 |
8167899 | Justis et al. | May 2012 | B2 |
8235945 | Baid | Aug 2012 | B2 |
8246584 | Aravena et al. | Aug 2012 | B2 |
8273053 | Saltzstein | Sep 2012 | B2 |
8292891 | Browne et al. | Oct 2012 | B2 |
8308693 | Miller et al. | Nov 2012 | B2 |
8333769 | Browne et al. | Dec 2012 | B2 |
8356598 | Rumsey | Jan 2013 | B2 |
8357163 | Sidebotham et al. | Jan 2013 | B2 |
8388541 | Messerly et al. | Mar 2013 | B2 |
8388623 | Browne et al. | Mar 2013 | B2 |
8414539 | Kuracina et al. | Apr 2013 | B1 |
8419683 | Miller et al. | Apr 2013 | B2 |
8480632 | Miller et al. | Jul 2013 | B2 |
8480672 | Browne et al. | Jul 2013 | B2 |
8486027 | Findlay et al. | Jul 2013 | B2 |
8506568 | Miller | Aug 2013 | B2 |
8535271 | Fuchs et al. | Sep 2013 | B2 |
8562615 | Browne et al. | Oct 2013 | B2 |
8641715 | Miller | Feb 2014 | B2 |
8647257 | Jansen et al. | Feb 2014 | B2 |
8656929 | Miller et al. | Feb 2014 | B2 |
8657790 | Tal et al. | Feb 2014 | B2 |
8663231 | Browne et al. | Mar 2014 | B2 |
8668698 | Miller et al. | Mar 2014 | B2 |
8684978 | Miller et al. | Apr 2014 | B2 |
8690791 | Miller | Apr 2014 | B2 |
8715287 | Miller | May 2014 | B2 |
8771230 | White et al. | Jul 2014 | B2 |
8781555 | Burnside et al. | Jul 2014 | B2 |
8801663 | Woehr | Aug 2014 | B2 |
8812101 | Miller et al. | Aug 2014 | B2 |
8814835 | Baid | Aug 2014 | B2 |
8821493 | Anderson | Sep 2014 | B2 |
8828001 | Stearns et al. | Sep 2014 | B2 |
8849382 | Cox et al. | Sep 2014 | B2 |
8870872 | Miller | Oct 2014 | B2 |
8894654 | Anderson | Nov 2014 | B2 |
8936575 | Moulton | Jan 2015 | B2 |
8944069 | Miller et al. | Feb 2015 | B2 |
8974410 | Miller et al. | Mar 2015 | B2 |
8998848 | Miller et al. | Apr 2015 | B2 |
9072543 | Miller et al. | Jul 2015 | B2 |
9078637 | Miller | Jul 2015 | B2 |
9149625 | Woehr et al. | Oct 2015 | B2 |
9173679 | Tzachar et al. | Nov 2015 | B2 |
9226756 | Teisen et al. | Jan 2016 | B2 |
9278195 | Erskine | Mar 2016 | B2 |
9295487 | Miller et al. | Mar 2016 | B2 |
9302077 | Domonkos et al. | Apr 2016 | B2 |
9314232 | Stark | Apr 2016 | B2 |
9314270 | Miller | Apr 2016 | B2 |
9358348 | Weilbacher et al. | Jun 2016 | B2 |
9393031 | Miller | Jul 2016 | B2 |
9414815 | Miller et al. | Aug 2016 | B2 |
9415192 | Kuracina et al. | Aug 2016 | B2 |
9421345 | Woehr et al. | Aug 2016 | B2 |
9427555 | Baid | Aug 2016 | B2 |
9433400 | Miller | Sep 2016 | B2 |
9439667 | Miller | Sep 2016 | B2 |
9439702 | Arthur et al. | Sep 2016 | B2 |
9445743 | Kassab | Sep 2016 | B2 |
9451968 | Miller et al. | Sep 2016 | B2 |
9451983 | Windolf | Sep 2016 | B2 |
9456766 | Cox et al. | Oct 2016 | B2 |
9480483 | Browne et al. | Nov 2016 | B2 |
9492097 | Wilkes et al. | Nov 2016 | B2 |
9504477 | Miller et al. | Nov 2016 | B2 |
9521961 | Silverstein et al. | Dec 2016 | B2 |
9545243 | Miller et al. | Jan 2017 | B2 |
9554716 | Burnside et al. | Jan 2017 | B2 |
9615816 | Woodard | Apr 2017 | B2 |
9615838 | Nino et al. | Apr 2017 | B2 |
9623210 | Woehr | Apr 2017 | B2 |
9636031 | Cox | May 2017 | B2 |
9636484 | Baid | May 2017 | B2 |
9649048 | Cox et al. | May 2017 | B2 |
9681889 | Greenhalgh et al. | Jun 2017 | B1 |
9687633 | Teoh | Jun 2017 | B2 |
9717564 | Miller et al. | Aug 2017 | B2 |
9730729 | Kilcoin et al. | Aug 2017 | B2 |
9782546 | Woehr | Oct 2017 | B2 |
9839740 | Beamer et al. | Dec 2017 | B2 |
9844646 | Knutsson | Dec 2017 | B2 |
9844647 | Knutsson | Dec 2017 | B2 |
9872703 | Miller et al. | Jan 2018 | B2 |
9883853 | Woodard et al. | Feb 2018 | B2 |
9895512 | Kraft et al. | Feb 2018 | B2 |
9962211 | Csernatoni | May 2018 | B2 |
10052111 | Miller et al. | Aug 2018 | B2 |
10092320 | Morgan et al. | Oct 2018 | B2 |
10092706 | Denzer et al. | Oct 2018 | B2 |
10159531 | Misener et al. | Dec 2018 | B2 |
10172538 | Kassab | Jan 2019 | B2 |
10413211 | Kassab | Sep 2019 | B2 |
10449330 | Newman et al. | Oct 2019 | B2 |
D898908 | Denzer et al. | Oct 2020 | S |
10893887 | Blanchard | Jan 2021 | B2 |
10973532 | Miller et al. | Apr 2021 | B2 |
10973545 | Miller et al. | Apr 2021 | B2 |
10980522 | Muse | Apr 2021 | B2 |
11298202 | Miller et al. | Apr 2022 | B2 |
11446112 | Fink et al. | Sep 2022 | B2 |
11896264 | Lindekugel et al. | Feb 2024 | B2 |
20030060781 | Mogensen et al. | Mar 2003 | A1 |
20030225344 | Miller | Dec 2003 | A1 |
20030225411 | Miller | Dec 2003 | A1 |
20030229308 | Tsals et al. | Dec 2003 | A1 |
20040010236 | Morawski et al. | Jan 2004 | A1 |
20040059317 | Hermann | Mar 2004 | A1 |
20040220497 | Findlay et al. | Nov 2004 | A1 |
20040243135 | Koseki | Dec 2004 | A1 |
20050035014 | Cane | Feb 2005 | A1 |
20050101912 | Faust et al. | May 2005 | A1 |
20050113866 | Heinz et al. | May 2005 | A1 |
20050131345 | Miller | Jun 2005 | A1 |
20050165403 | Miller | Jul 2005 | A1 |
20060015066 | Turieo et al. | Jan 2006 | A1 |
20060020191 | Brister et al. | Jan 2006 | A1 |
20060025723 | Ballarini | Feb 2006 | A1 |
20060058826 | Evans et al. | Mar 2006 | A1 |
20070049945 | Miller | Mar 2007 | A1 |
20070096690 | Casalena et al. | May 2007 | A1 |
20070151116 | Malandain | Jul 2007 | A1 |
20070191772 | Wojcik | Aug 2007 | A1 |
20070270775 | Miller et al. | Nov 2007 | A1 |
20070276352 | Crocker et al. | Nov 2007 | A1 |
20070282344 | Yedlicka et al. | Dec 2007 | A1 |
20080015467 | Miller | Jan 2008 | A1 |
20080154304 | Crawford et al. | Jun 2008 | A1 |
20080208136 | Findlay et al. | Aug 2008 | A1 |
20080215056 | Miller et al. | Sep 2008 | A1 |
20080221580 | Miller et al. | Sep 2008 | A1 |
20080257359 | Rumsey | Oct 2008 | A1 |
20090048575 | Waters | Feb 2009 | A1 |
20090054808 | Miller | Feb 2009 | A1 |
20090093830 | Miller | Apr 2009 | A1 |
20090194446 | Miller et al. | Aug 2009 | A1 |
20090204024 | Miller | Aug 2009 | A1 |
20090306697 | Fischvogt | Dec 2009 | A1 |
20100004606 | Hansen et al. | Jan 2010 | A1 |
20100174243 | McKay | Jul 2010 | A1 |
20100204649 | Miller et al. | Aug 2010 | A1 |
20100286607 | Saltzstein | Nov 2010 | A1 |
20100298830 | Browne et al. | Nov 2010 | A1 |
20100298831 | Browne et al. | Nov 2010 | A1 |
20100312246 | Browne et al. | Dec 2010 | A1 |
20110004163 | Vaidya | Jan 2011 | A1 |
20110028976 | Miller | Feb 2011 | A1 |
20110202065 | Takizawa et al. | Aug 2011 | A1 |
20120116390 | Madan | May 2012 | A1 |
20120116394 | Timm et al. | May 2012 | A1 |
20120202180 | Stock et al. | Aug 2012 | A1 |
20120203154 | Tzachar | Aug 2012 | A1 |
20120274280 | Yip et al. | Nov 2012 | A1 |
20130030439 | Browne et al. | Jan 2013 | A1 |
20130041345 | Kilcoin et al. | Feb 2013 | A1 |
20130072938 | Browne et al. | Mar 2013 | A1 |
20130102924 | Findlay et al. | Apr 2013 | A1 |
20130158484 | Browne et al. | Jun 2013 | A1 |
20130178807 | Baid | Jul 2013 | A1 |
20140031674 | Newman et al. | Jan 2014 | A1 |
20140031794 | Windolf | Jan 2014 | A1 |
20140039400 | Browne et al. | Feb 2014 | A1 |
20140081281 | Felder | Mar 2014 | A1 |
20140142577 | Miller | May 2014 | A1 |
20140171873 | Mark | Jun 2014 | A1 |
20140188133 | Misener | Jul 2014 | A1 |
20140221970 | Eaton et al. | Aug 2014 | A1 |
20140262408 | Woodard | Sep 2014 | A1 |
20140262880 | Yoon | Sep 2014 | A1 |
20140276205 | Miller et al. | Sep 2014 | A1 |
20140276206 | Woodward et al. | Sep 2014 | A1 |
20140276471 | Emery et al. | Sep 2014 | A1 |
20140276833 | Larsen et al. | Sep 2014 | A1 |
20140276839 | Forman et al. | Sep 2014 | A1 |
20140343454 | Miller et al. | Nov 2014 | A1 |
20140343497 | Baid | Nov 2014 | A1 |
20150011941 | Saeki | Jan 2015 | A1 |
20150045732 | Murphy et al. | Feb 2015 | A1 |
20150080762 | Kassab et al. | Mar 2015 | A1 |
20150126931 | Holm et al. | May 2015 | A1 |
20150196737 | Baid | Jul 2015 | A1 |
20150223786 | Morgan et al. | Aug 2015 | A1 |
20150230823 | Morgan et al. | Aug 2015 | A1 |
20150238733 | Bin Abdulla | Aug 2015 | A1 |
20150342615 | Keinan et al. | Dec 2015 | A1 |
20150342756 | Bays et al. | Dec 2015 | A1 |
20150351797 | Miller et al. | Dec 2015 | A1 |
20150366569 | Miller | Dec 2015 | A1 |
20150367487 | Nino et al. | Dec 2015 | A1 |
20160009812 | Satelli et al. | Jan 2016 | A1 |
20160022282 | Miller et al. | Jan 2016 | A1 |
20160022284 | Lele et al. | Jan 2016 | A1 |
20160039916 | Jiang et al. | Feb 2016 | A1 |
20160058432 | Miller | Mar 2016 | A1 |
20160066954 | Miller et al. | Mar 2016 | A1 |
20160136410 | Aklog et al. | May 2016 | A1 |
20160183974 | Miller | Jun 2016 | A1 |
20160184509 | Miller et al. | Jun 2016 | A1 |
20160235949 | Baid | Aug 2016 | A1 |
20160305497 | Victor et al. | Oct 2016 | A1 |
20160354539 | Tan et al. | Dec 2016 | A1 |
20160361519 | Teoh et al. | Dec 2016 | A1 |
20170020533 | Browne et al. | Jan 2017 | A1 |
20170020560 | Van Citters et al. | Jan 2017 | A1 |
20170021138 | Sokolski | Jan 2017 | A1 |
20170043135 | Knutsson | Feb 2017 | A1 |
20170105763 | Karve et al. | Apr 2017 | A1 |
20170136217 | Riesenberger et al. | May 2017 | A1 |
20170151419 | Sonksen | Jun 2017 | A1 |
20170156740 | Stark | Jun 2017 | A9 |
20170156751 | Csernatoni | Jun 2017 | A1 |
20170209129 | Fagundes et al. | Jul 2017 | A1 |
20170231644 | Anderson | Aug 2017 | A1 |
20170303962 | Browne et al. | Oct 2017 | A1 |
20170303963 | Kilcoin et al. | Oct 2017 | A1 |
20180049772 | Brockman et al. | Feb 2018 | A1 |
20180092662 | Rioux et al. | Apr 2018 | A1 |
20180116551 | Newman et al. | May 2018 | A1 |
20180116642 | Woodard et al. | May 2018 | A1 |
20180116693 | Blanchard et al. | May 2018 | A1 |
20180117262 | Islam | May 2018 | A1 |
20180125465 | Muse et al. | May 2018 | A1 |
20180153474 | Aeschlimann et al. | Jun 2018 | A1 |
20180154112 | Chan et al. | Jun 2018 | A1 |
20180221003 | Hibner et al. | Aug 2018 | A1 |
20180228509 | Fojtik | Aug 2018 | A1 |
20180242982 | Laughlin et al. | Aug 2018 | A1 |
20190059986 | Shelton, IV et al. | Feb 2019 | A1 |
20190069812 | Isaacson et al. | Mar 2019 | A1 |
20190083753 | Chu | Mar 2019 | A1 |
20190150954 | Xie | May 2019 | A1 |
20190175220 | Coppedge et al. | Jun 2019 | A1 |
20190282244 | Muse | Sep 2019 | A1 |
20200054347 | Coppedge et al. | Feb 2020 | A1 |
20200054410 | Pfotenhauer et al. | Feb 2020 | A1 |
20200113584 | McGinley et al. | Apr 2020 | A1 |
20200129186 | Miller et al. | Apr 2020 | A1 |
20200197121 | Morey et al. | Jun 2020 | A1 |
20200297382 | Coppedge et al. | Sep 2020 | A1 |
20200297452 | Coppedge et al. | Sep 2020 | A1 |
20200337782 | Glassman et al. | Oct 2020 | A1 |
20210015529 | Fenton, Jr. | Jan 2021 | A1 |
20210093357 | Pett et al. | Apr 2021 | A1 |
20210093358 | Lindekugel et al. | Apr 2021 | A1 |
20210113251 | Vogt et al. | Apr 2021 | A1 |
20210282812 | Tierney et al. | Sep 2021 | A1 |
20210322055 | Lindekugel et al. | Oct 2021 | A1 |
20210375445 | Lindekugel et al. | Dec 2021 | A1 |
20210393337 | Zucker | Dec 2021 | A1 |
20220240976 | Pett et al. | Aug 2022 | A1 |
20220249104 | Pett et al. | Aug 2022 | A1 |
20220273338 | Eisenthal et al. | Sep 2022 | A1 |
20230106545 | Pett et al. | Apr 2023 | A1 |
20230285049 | Howell | Sep 2023 | A1 |
20230414251 | Pett et al. | Dec 2023 | A1 |
20240058036 | Lindekugel et al. | Feb 2024 | A1 |
20240206887 | Pett et al. | Jun 2024 | A1 |
20240261554 | Akerele-Ale et al. | Aug 2024 | A1 |
20240277375 | Lindekugel et al. | Aug 2024 | A1 |
Number | Date | Country |
---|---|---|
108742795 | Nov 2018 | CN |
110547847 | Dec 2019 | CN |
0923961 | Jun 1999 | EP |
3687024 | Jul 2020 | EP |
2390297 | Nov 2012 | ES |
2581548 | Nov 1986 | FR |
2018509969 | Apr 2018 | JP |
20090006621 | Jan 2009 | KR |
2007018809 | Feb 2007 | NO |
1997024151 | Jul 1997 | WO |
1998052638 | Feb 1999 | WO |
2005046769 | May 2005 | WO |
05041790 | May 2005 | WO |
2005053506 | Jun 2005 | WO |
2005072625 | Aug 2005 | WO |
2008002961 | Jan 2008 | WO |
2008016757 | Feb 2008 | WO |
2008033871 | Mar 2008 | WO |
2008033872 | Mar 2008 | WO |
2008033873 | Mar 2008 | WO |
2008033874 | Mar 2008 | WO |
2008054894 | May 2008 | WO |
2008086258 | Jul 2008 | WO |
2008124206 | Oct 2008 | WO |
2008124463 | Oct 2008 | WO |
2008130893 | Oct 2008 | WO |
2008134355 | Nov 2008 | WO |
2008144379 | Nov 2008 | WO |
2009070896 | Jun 2009 | WO |
2010043043 | Apr 2010 | WO |
2011070593 | Jun 2011 | WO |
2011097311 | Aug 2011 | WO |
2011139294 | Nov 2011 | WO |
2013003885 | Jan 2013 | WO |
2013009901 | Jan 2013 | WO |
2013173360 | Nov 2013 | WO |
2014075165 | May 2014 | WO |
2014142948 | Sep 2014 | WO |
2014144239 | Sep 2014 | WO |
2014144262 | Sep 2014 | WO |
2014144489 | Sep 2014 | WO |
2014144757 | Sep 2014 | WO |
2014144797 | Sep 2014 | WO |
2015061370 | Apr 2015 | WO |
2015177612 | Nov 2015 | WO |
2016033016 | Mar 2016 | WO |
16053834 | Apr 2016 | WO |
2016085973 | Jun 2016 | WO |
2016163939 | Oct 2016 | WO |
18006045 | Jan 2018 | WO |
2018025094 | Feb 2018 | WO |
2018058036 | Mar 2018 | WO |
2018075694 | Apr 2018 | WO |
18098086 | May 2018 | WO |
2018165334 | Sep 2018 | WO |
2018165339 | Sep 2018 | WO |
2019051343 | Mar 2019 | WO |
2019164990 | Aug 2019 | WO |
2021011795 | Jan 2021 | WO |
2021016122 | Jan 2021 | WO |
2021062385 | Apr 2021 | WO |
2021062038 | Apr 2021 | WO |
2021062394 | Apr 2021 | WO |
2022165232 | Aug 2022 | WO |
2022170269 | Aug 2022 | WO |
2023177634 | Sep 2023 | WO |
2024163884 | Aug 2024 | WO |
Entry |
---|
PCT/US2024/014241 filed Feb. 2, 2024 International Search Report and Written Opinion dated May 8, 2024. |
U.S. Appl. No. 17/335,870, filed Jun. 1, 2021 Final Office Action dated Mar. 26, 2024. |
U.S. Appl. No. 17/405,692, filed Aug. 18, 2021 Restriction Requirement dated May 10, 2024. |
U.S. Appl. No. 18/385,056, filed Oct. 30, 2023 Non-Final Office Action dated May 9, 2024. |
U.S. Appl. No. 17/031,650, filed Sep. 24, 2020 Non-Final Office Action dated Jan. 19, 2022. |
PCT/US2021/ 046573 filed Aug. 18, 2021 International Search Report and Written Opinion dated Nov. 30, 2021. |
PCT/US2021/ 047378 filed Aug. 24, 2021 International Search Report and Written Opinion dated Nov. 17, 2021. |
PCT/US2021/ 048542 filed Aug. 31, 2021 International Search Report and Written Opinion dated Dec. 9, 2021. |
PCT/US2021/ 049475 filed Sep. 8, 2021 International Search Report and Written Opinion dated Dec. 9, 2021. |
EP 19757667.1 filed Sep. 18, 2020 Extended European Search Report dated Oct. 22, 2021. |
EP 20867024.0 filed Apr. 21, 2022 Extended European Search Report dated Aug. 8, 2023. |
EP 20868351.6 filed Apr. 21, 2022 Extended European Search Report dated Aug. 10, 2023. |
EP 23166984.7 filed Apr. 6, 2023 Extended European Search Report dated Jul. 5, 2023. |
PCT/US2023/015127 filed Mar. 13, 2023 International Search Report and Written Opinion dated Jun. 26, 2023. |
U.S. Appl. No. 17/035,272, filed Sep. 28, 2020 Notice of Allowance dated Jul. 7, 2023. |
U.S. Appl. No. 17/235,134, filed Apr. 20, 2021 Non-Final Office Action dated Jun. 27, 2023. |
U.S. Appl. No. 17/335,870, filed Jun. 1, 2021 Restriction Requirement dated Jul. 25, 2023. |
U.S. Appl. No. 17/667,291, filed Feb. 8, 2022 Non-Final Office Action dated Aug. 31, 2023. |
U.S. Appl. No. 17/337,100, filed Jun. 2, 2021 Notice of Allowance dated Jan. 24, 2024. |
U.S. Appl. No. 17/469,613, filed Sep. 8, 2021 Non-Final Office Action dated Jan. 19, 2024. |
Ekchian Gregory James et al: “Quantitative Methods for In Vitro and In Vivo Characterization of Cell and Tissue Metabolism”, Jun. 11, 2018, XP055839281, retrieved from the internet on Sep. 8, 2021 : URL: https://dspace.mit.edu/bitstream/handle/1721.1/117890/1051211749-MIT.pdf?sequence=1&isAllowed=y. |
PCT/US2019/ 018828 filed Feb. 20, 2019 International Preliminary Report on Patentability dated Aug. 27, 2020. |
PCT/US2019/ 018828 filed Feb. 20, 2019 International Search Report and Written Opinion dated Jun. 13, 2019. |
PCT/US2020/ 053119 filed Sep. 28, 2020 International Search Report and Written Opinion dated Jan. 5, 2021. |
PCT/US2020/052558 filed Sep. 24, 2020 International Search Report and Written Opinion dated Feb. 11, 2021. |
PCT/US2020/053135 filed Sep. 28, 2020 International Search Report and Written Opinion dated Dec. 18, 2020. |
PCT/US2021/ 035232 filed Jun. 1, 2021 International Search Report and Written Opinion dated Oct. 19, 2021. |
PCT/US2021/028114 filed Apr. 20, 2021 International Search Report and Written Opinion dated Jul. 12, 2021. |
PCT/US2021/035475 filed Jun. 2, 2021 International Search Report and Written Opinion dated Sep. 17, 2021. |
PCT/US2022/014391 filed Jan. 28, 2022 International Search Report and Written Opinion dated Apr. 14, 2022. |
PCT/US2022/015686 filed Feb. 8, 2022 International Search Report and Written Opinion dated May 25, 2022. |
U.S. Appl. No. 17/031,650, filed Sep. 24, 2020 Final Office Action dated Jul. 20, 2022. |
U.S. Appl. No. 17/035,336, filed Sep. 28, 2020 Restriction Requirement dated Jul. 26, 2022. |
U.S. Appl. No. 17/235,134, filed Apr. 20, 2021 Notice of Allowance dated Sep. 20, 2023. |
U.S. Appl. No. 17/335,870, filed Jun. 1, 2021 Non-Final Office Action dated Nov. 15, 2023. |
U.S. Appl. No. 17/337,100, filed Jun. 2, 2021 Final Office Action dated Nov. 21, 2023. |
U.S. Appl. No. 17/469,613, filed Sep. 8, 2021 Restriction Requirement dated Oct. 23, 2023. |
U.S. Appl. No. 17/863,898, filed Jul. 13, 2022 Final Office Action dated Nov. 22, 2023. |
U.S. Appl. No. 17/031,650, filed Sep. 24, 2020 Notice of Allowance dated Oct. 12, 2022. |
U.S. Appl. No. 17/035,272, filed Sep. 28, 2020 Non-Final Office Action dated Mar. 9, 2023. |
U.S. Appl. No. 17/035,272, filed Sep. 28, 2020 Restriction Requirement dated Dec. 9, 2022. |
U.S. Appl. No. 17/035,336, filed Sep. 28, 2020 Notice of Allowance dated Jan. 11, 2023. |
U.S. Appl. No. 17/235,134, filed Apr. 20, 2021 Restriction Requirement dated Mar. 7, 2023. |
U.S. Appl. No. 17/337,100, filed Jun. 2, 2021 Non-Final Office Action dated Jun. 2, 2023. |
U.S. Appl. No. 17/667,291, filed Feb. 8, 2022 Restriction Requirement dated May 31, 2023. |
U.S. Appl. No. 17/405,692, filed Aug. 18, 2021 Non-Final Office Action dated Sep. 6, 2024. |
U.S. Appl. No. 17/463,324, filed Aug. 31, 2021 Non-Final Office Action dated Oct. 30, 2024. |
U.S. Appl. No. 17/463,324, filed Aug. 31, 2021 Restriction Requirement dated Aug. 8, 2024. |
U.S. Appl. No. 17/587,900, filed Jan. 28, 2022 Non-Final Office Action dated Nov. 14, 2024. |
U.S. Appl. No. 18/075,269, filed Dec. 5, 2022 Non-Final Office Action dated Jun. 24, 2024. |
U.S. Appl. No. 18/075,269, filed Dec. 5, 2022 Notice of Allowance dated Sep. 11, 2024. |
U.S. Appl. No. 18/244,730, filed Sep. 11, 2023 Final Office Action dated Aug. 8, 2024. |
U.S. Appl. No. 18/244,730, filed Sep. 11, 2023 Non-Final Office Action dated May 3, 2024. |
U.S. Appl. No. 18/244,730, filed Sep. 11, 2023 Notice of Allowance dated Oct. 24, 2024. |
U.S. Appl. No. 18/385,056, filed Oct. 30, 2023 Notice of Allowance dated Aug. 29, 2024. |
U.S. Appl. No. 17/405,692, filed Aug. 18, 2021 Final Office Action dated Dec. 4, 2024. |
U.S. Appl. No. 17/469,613, filed Sep. 8, 2021 Final Office Action dated Dec. 6, 2024. |
Number | Date | Country | |
---|---|---|---|
20220061880 A1 | Mar 2022 | US |
Number | Date | Country | |
---|---|---|---|
63069988 | Aug 2020 | US |